Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 11, Issue 5, Pages 492-497Publisher
SPRINGER
DOI: 10.1007/s11910-011-0216-9
Keywords
Multiple sclerosis; MS; Therapy; Fingolimod; FTY720; T cell; TRANSFORMS; FREEDOMS
Categories
Funding
- Actelion
- Advancell
- Allozyne
- BaroFold
- Bayer Health Care Pharmaceuticals
- Bayer Schering Pharma
- Bayhill
- Biogen Idec
- BioMarin
- CLC Behring
- Elan
- Genmab
- GeNeuro SA
- Genmark
- GlaxoSmithKline
- Eli Lilly
- Merck Serono
- MediciNova
- Novartis
- Novonordisk
- Pepimmune
- Sanofi-Aventis
- Santhera
- Roche
- Teva
- UCB
- Wyeth
- Swiss MS Society
- Swiss National Research Foundation
- European Union
- Gianni Rubatto
- Roche Research Foundations
- Bayer Schering
Ask authors/readers for more resources
The oral sphingosine 1-phosphate receptor (S1PR) modulator fingolimod functionally antagonizes S1PR hereby blocking lymphocyte egress from secondary lymphoid organs to the peripheral blood circulation. This results in a reduction in peripheral lymphocyte counts, including potentially encephalitogenic T cells. In patients with relapsing multiple sclerosis fingolimod has been shown to be an effective treatment. In phase 2 and phase 3 studies fingolimod-treated patients had reduced disease activity clinically and in MRI. Although severe infectious complications occurred in single cases treated with fingolimod, the frequency of overall infections was comparable in fingolimod-treated patients and controls. Overall, in clinical studies fingolimod was well tolerated and had a favorable safety profile. In follow-up studies with continuous fingolimod, treatment showed sustained efficacy while being well tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available